According to recent findings appearing in the April 2009 print issue of the Clinical Journal of the American Society of Nephrology (CJASN), rituximab may be highly effective for treating a kidney disorder, membranous nephropathy.

Present treatments for this disorder are limited to steroids, chemotherapeutic agents, and calcineurin inhibitors and all of them have some considerable side effects.

From News-Medical.Net:

The available data suggest that current rituximab dosing achieves a 15% to 20% rate of complete remission and a 35% to 40% rate of partial remission: rates similar to the response rates of current treatments. Importantly, rituximab appears to be well-tolerated with minimal short-term side effects.

Rituximab may have potential for treating membranous nephropathy, but additional studies – in particular, randomized controlled clinical trials – are needed to prove the drug’s value. “Our conclusion is that, at present, rituximab should only be used in research settings,” said Dr. Bomback.

The authors reported no financial disclosures.

Andrew Bomback, MD (University of North Carolina Kidney Center), and his colleagues, completed this study that highlighted the fact that rituximab dosing was able to achieve a 15-20 percent rate of complete remission and 35-40 percent of partial remission.

It is believed that this study on membranous nephropathy would provide a path-breaking treatment option.

Tags: kidney disorder, membranous nephropathy, rituximab, steroids

Posted in buy steroids, Steroid Cycles, steroid nation, Steroids and Anabolic Steroids